Grants and Contributions:

Title:

Developing Novel Nano Formulations of Poorly Soluble Active Ingredients To Act As Anti-Inflammatory And Antioxidant Agents in Humans.

Agreement Number:

1031138

Agreement Value:

$75,000.00

Agreement Date:

Jun 1, 2025 - Feb 28, 2026

Description:

Pividl's Micellosomes are a novel nano-delivery system used to deliver hard to solubilize and poorly bioavailable compounds. This project is aimed at demonstrating how Micellosomes can be used to deliver anti-inflammatory molecules that have the potential to provide radiation protection and reduce the impacts of radiation / inflammation exposure on and in the human body. Formulations produced will be standardised and validated for stability, encapsulation efficiency and bioavailability kinetics in order to demonstrate their ability to prevent and reduce radiation induced inflammation in Microvascular endothelial cells and anti-inflammatory responses in human Embryonic kidney cells, cardiovascular cells and blood-brain-barrier cells.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Moncton, New Brunswick, CA E1C 4X7

Reference Number:

172-2025-2026-Q1-1031138

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

730916079

Recipient Type:

For-profit organization

Recipient's Legal Name:

Pividl Bioscience Inc.

Federal Riding Name:

Moncton--Riverview--Dieppe

Federal Riding Number:

13007

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

33149